Postprandial hyperglycemia

Why do we care about it? What should we do?

Marc S. Rendell

Research output: Contribution to journalArticle

Abstract

There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.

Original languageEnglish
Pages (from-to)582-586
Number of pages5
JournalDrug Development Research
Volume67
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Hyperglycemia
Glucose
Plasmas
Meals
Fasting
Disaccharidases
Insulin
Dipeptidyl-Peptidase IV Inhibitors
Thiazolidinediones
Glucagon-Like Peptide 1
Glucose Intolerance
Metformin
Hypoglycemia
Medical problems
Blood Vessels
Availability
Monitoring

All Science Journal Classification (ASJC) codes

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Postprandial hyperglycemia : Why do we care about it? What should we do? / Rendell, Marc S.

In: Drug Development Research, Vol. 67, No. 7, 07.2006, p. 582-586.

Research output: Contribution to journalArticle

@article{7f3e12624f7442c087dfb4dfb4ccbfe5,
title = "Postprandial hyperglycemia: Why do we care about it? What should we do?",
abstract = "There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.",
author = "Rendell, {Marc S.}",
year = "2006",
month = "7",
doi = "10.1002/ddr.20127",
language = "English",
volume = "67",
pages = "582--586",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Postprandial hyperglycemia

T2 - Why do we care about it? What should we do?

AU - Rendell, Marc S.

PY - 2006/7

Y1 - 2006/7

N2 - There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.

AB - There is increasing evidence that elevated postprandial plasma glucose (PPG) exerts a more deleterious effect on the vascular system than elevation of fasting plasma glucose (FPG). In particular, individuals with normal FPG but impaired glucose tolerance (IGT) have significantly increased risk of cardiovascular events. With the recognition of the importance of PPG and the availability of new pharmacologic options, management of diabetes will shift to greater attention to PPG levels. There are many approaches to reduction of PPG; dietary management and promotion of exercise are very effective. Sulfonylureas, meglitinides, metformin, thiazolidinediones, and disaccharidase inhibitors all counteract PPG elevation. The development of glucagon-like peptide-1 (GLP-1) agonists such as exendin and dipeptidyl peptidase IV inhibitors offers a new approach to suppression of PPG elevation. New semisynthetic insulin analogues permit a more aggressive response to post-prandial glucose elevation, with lower risk of hypoglycemia, than with regular insulin. The advent of accurate continuous glucose monitoring will facilitate the treatment of post-prandial hyperglycemia.

UR - http://www.scopus.com/inward/record.url?scp=33845201944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845201944&partnerID=8YFLogxK

U2 - 10.1002/ddr.20127

DO - 10.1002/ddr.20127

M3 - Article

VL - 67

SP - 582

EP - 586

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 7

ER -